Groh, Laszlo A.
Willems, Loes H. http://orcid.org/0000-0002-2728-9663
Fintelman, Paula
Reijnen, Michel M. P. J.
El Messaoudi, Saloua
Warlé, Michiel C.
Clinical trials referenced in this document:
Documents that mention this clinical trial
Dual-Pathway Inhibition with Rivaroxaban and Low-Dose Aspirin Does Not Alter Immune Cell Responsiveness and Distribution in Patients with Coronary Artery Disease
https://doi.org/10.1007/s40119-023-00342-5
Article History
Received: 7 September 2023
Accepted: 8 November 2023
First Online: 6 December 2023
Declarations
:
: Laszlo A. Groh, Loes H. Willems, Paula Fintelman, Michel M.P.J. Reijnen, Saloua El Messaoudi, and Michiel C. Warlé have nothing to disclose.
: Approval of the Medical Research Ethics Committee Oost-Nederland (file number 2021-13291) and the local institutional review board was obtained. This study was conducted in accordance with the latest revision of the Helsinki Declaration of 1964 and Good Clinical Practice regulations and was registered at ClinicalTrials.gov on January 27, 2022 (registration number NCT05210725). Written informed consent was obtained from all participants.